Clinical Trial

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 13, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-2-307-ADC in patients with advanced cancer
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2021-12-01; most recent amendment 2026-01-09.
Status change: Recruiting → Active, Not Recruiting 2026-01-09
Status change: Not Yet Recruiting → Recruiting 2022-02-10
Trial Details
NCT Number NCT05156866
Lead Sponsor TORL Biotherapeutics, LLC
Collaborators: Translational Research in Oncology
Conditions Advanced Solid Tumor, Gastric Cancer, Pancreas Cancer, Gastroesophageal Junction Adenocarcinoma
Enrollment 163 participants
Start Date 2022-02-02
Primary Completion 2026-06-15 (estimated)
Study Completion 2027-02-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-13